Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody,131I-A5B7, even at doses that are sub-optimal for vascular shut-down

International Journal of Oncology

Volumn 30, Issue 2, 2007, Pages 453-460

  Lankester, Katharine J ^a   Maxwell, Ross J ^a   Pedley, R Barbara ^b   Dearling, Jason L ^b   Qureshi, Uzma A ^b   El Emir, Ethaar ^b   Hill, Sally A ^a   Tozer, Gillian M ^a,c  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

131I A5B7; CA 4 P; MRI; Radioimmunotherapy; Vascular disrupting agents

Indexed keywords

A5B7 MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; COMBRETASTATIN A 4; COMBRETASTATIN A-4; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG POTENTIATION; HUMAN; INSTRUMENTATION; KINETICS; METABOLISM; METHODOLOGY; MOUSE; MULTIMODALITY CANCER THERAPY; NECROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOIMMUNOTHERAPY; TIME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CLINICAL TRIALS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DRUG SYNERGISM; HUMANS; IODINE RADIOISOTOPES; KINETICS; MAGNETIC RESONANCE IMAGING; MICE; NECROSIS; NEOPLASM TRANSPLANTATION; RADIOIMMUNOTHERAPY; STILBENES; TIME FACTORS;

EID: 34047271956     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Napier M and Begent R: Radioimmunotherapy of gastrointestinal cancer. In: Cancer Radioimmunotherapy. Riva P (ed). Harwood Academia, Boston, MA, pp333-388, 1998.
2. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329: 1219-1224, 1993.
3. 131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96: 1259-1266, 2000.
4. Goldenberg DM: Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43: 693-713, 2002.
5. Jain RK and Baxter LT: Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48: 7022-7032, 1988.
6. Jain RK: Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81: 570-576, 1989.
7. Pedley RB, El-Emir E, Flynn AA, et al: Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys 54: 1524-1531, 2002.
8. Flynn AA, Green AJ, Boxer GM, Casey JL, Pedley RB and Begent RH: A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model. Int J Radiat Oncol Biol Phys 43: 183-189, 1999.
9. Boucher Y, Baxter LT and Jain RK: Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50: 4478-4484, 1990.
10. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR and Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res 57: 1829-1834, 1997.
11. Chaplin DJ, Pettit GR and Hill SA: Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19: 189-195, 1999.
12. Grosios K, Holwell SE, McGown AT, Pettit GR and Bibby MC: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81: 1318-1327, 1999.
13. Tozer GM, Prise VE, Wilson J, et al: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59: 1626-1634, 1999.
14. Kanthou C and Tozer GM: The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99: 2060-2069, 2002.
15. Prise VE, Honess DJ, Stratford MR, Wilson J and Tozer GM: The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 21: 717-726, 2002.
16. Bohle AS, Leuschner I, Kalthoff H and Henne-Bruns D: Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation. Int J Cancer 87: 838-843, 2000.
17. Hill SA, Chaplin DJ, Lewis G and Tozer GM: Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Int J Cancer 102: 70-74, 2002.
18. Chaplin D and Hill S: The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 54: 1491-1496, 2002. (Pubitemid 35380054)
19. Grosios K, Loadman PM, Swaine DJ, Pettit GR and Bibby MC: Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 20: 229-233, 2000.
20. Siemann DW, Mercer E, Lepler S and Rojiani AM: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99: 1-6, 2002.
21. Li L, Rojiani A and Siemann D: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 42: 899-903, 1998.
22. Murata R, Siemann DW, Overgaard J and Horsman MR: Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60: 155-161, 2001.
23. Horsman MR and Murata R: Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 54: 1518-1523, 2002.
24. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE and Brindle KM: Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 77: 1761-1767, 1998.
25. Beauregard DA, Hill SA, Chaplin DJ and Brindle KM: The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 61: 6811-6815, 2001.
26. Beauregard DA, Pedley RB, Hill SA and Brindle KM: Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 15: 99-105, 2002.
27. Maxwell R, Wilson J, Prise V, et al: Evaluation of the antivascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 15: 89-98, 2002.
28. Dowlati A, Robertson K, Cooney M, et al: A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408-3416, 2002.
29. Evelhoch JL, Lo Russo PM, He Z, et al: Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10: 3650-3657, 2004.
30. Robinson SP, McIntyre DJ, Checkley D, et al: Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88: 1592-1597, 2003.
31. Galbraith SM, Maxwell RJ, Lodge MA, et al: Combretastatin A4 phosphate has tumour anti-vascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21: 2831-2842, 2003.
32. Stevenson JP, Rosen M, Sun W, et al: Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21: 4428-4438, 2003.
33. Tofts PS and Kermode AG: Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17: 357-367, 1991.
34. Tofts PS: Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7: 91-101, 1997.
35. Pedley R, Hill S, Boxer G, et al: Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res 61: 4716-4722, 2001.
36. Richman PI and Bodmer WF: Control of differentiation in human colorectal carcinoma cell lines: epithelial-mesenchymal interactions. J Pathol 156: 197-211, 1988.
37. Sharma SK, Pedley RB, Bhatia J, et al: Sustained tumor regression of human colorectal cancer xenografts using a multi-functional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin Cancer Res 11: 814-825, 2005.
38. Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H and Kramer J: Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med 31: 567-571, 1994.
39. Donahue K, Burstein D, Manning W and Gray M: Studies of Gd-DTPA relaxivity and proton exchange rates in tissue. Magn Reson Med 32: 66-76, 1994.
40. Furman-Haran E, Margalit R, Grobgeld D and Degani H: Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. Proc Natl Acad Sci USA 93: 6247-6251, 1996.
41. Evelhoch JL: Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10: 254-259, 1999.
42. Kety S: Blood-tissue exchange methods. Theory of blood-tissue exchange and its application to measurement of blood flow. Meth Med Res 8: 223-227, 1960.
43. Chalkley H: Method for the quantitative morphologic analysis of tissues. J Natl Cancer Inst 4: 47-53, 1943.
44. Smith KA, Hill SA, Begg AC and Denekamp J: Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer 57: 247-253, 1988.
45. Lyng H, Dahle GA, Kaalhus O, Skretting A and Rofstad EK: Measurement of perfusion rate in human melanoma xenografts by contrast-enhanced magnetic resonance imaging. Magn Reson Med 40: 89-98, 1998.
46. Checkley D, Tessier JJ, Kendrew J, Waterton JC and Wedge SR: Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89: 1889-1895, 2003.
47. Weinmann HJ, Laniado M and Mutzel W: Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 16: 167-172, 1984.
48. Maxwell R, Wilson J, Tozer G, Barber P and Vojnovic B: Segmentation of magnetic resonance images according to contrast agent uptake kinetics using a competitive neural network. In: Artificial Neural Networks in Medicine and Biology. Malmgren H, Borga M and Niklasson L (eds). Springer-Verlag, London, pp93-98, 2000.
49. Chodera A and Feller K: Some aspects of pharmacokinetic and biotransformation differences in humans and mammal animals. Int J Clin Pharmacol Biopharm 16: 357-360, 1978.
50. Rustin GJ, Galbraith SM, Anderson H, et al: Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21: 2815-2822, 2003. (Pubitemid 46621828)